Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Bicara Therapeutics Inc.
Headquarters: Boston, MA, United States of America
Website: https://www.bicara.com/
Year Founded: 2020
Status: Public
Industry Sector: N/A
CEO: N/A
Number Of Employees: N/A
Enterprise Value: N/A
PE Ratio: N/A
Exchange/Ticker 1: NASDAQ:BCAX
Exchange/Ticker 2: N/A
Latest Market Cap: $645,010,624
BioCentury | Oct 10, 2024
Finance
Down rounds don’t aid post-IPO performance
Neither private down rounds nor IPO step-downs correlate with market performance after IPOs
BioCentury | Sep 17, 2024
Finance
IPOs, GLP-1 vs. PD-1, and AI in biotech: a BioCentury podcast
Do last week’s trio of NASDAQ debuts signal an opening IPO window?
BioCentury | Sep 13, 2024
Finance
Trio of first-day pops may bode well for biotech IPO window
With three biotechs trading up after NASDAQ debuts, sustained positive performance could further open window
BioCentury | Sep 4, 2024
Finance
Light from the IPO window
Six recent filings may mean appetite for new listings is on the rise
BioCentury | Aug 30, 2024
Finance
Finance Report: RA, Forbion back immunology play Navigator to develop bispecific
Plus: Series A for oncology play Noetik; China-based DualityBio files for Hong Kong IPO
BioCentury | Aug 27, 2024
Finance
Biotech IPO buzz, pharma deal trends, Washington update — a BioCentury podcast
Three’s the charm as another IPO enters the queue
BioCentury | Aug 26, 2024
Finance
Three’s a crowd? MBX follows Bicara, Zenas into IPO queue
Indiana-based developer of long-acting peptide therapeutics is latest mid-to-late-stage biotech to seek NASDAQ listing
BioCentury | Aug 24, 2024
Finance
Public Equity Report: Signs of life for biotech IPOs as Zenas, Bicara file, TYK sticks landing
Pair of well-funded late-stage biotechs seek NASDAQ listings, Shanghai cancer company prices deal in Hong Kong
BioCentury | Aug 6, 2024
Finance
With an eye toward ‘inflection capital’ for biotechs, TPG focuses new fund on clinical POC
Firm has $580M in to invest in life sciences strategy
BioCentury | Mar 27, 2024
Management Tracks
Rocket names Mirati vet Ondrey CFO
Plus: Syed Rizvi joins Poseida as CMO, and updates from Tvardi, Echosens and Bicara
Items per page:
1 - 10 of 19